• In late May and early June 2026, BioNTech SE presented new clinical data at the ASCO Annual Meeting in Chicago, highlighting encouraging anti-tumor activity from its late-stage oncology candidates pumitamig and gotistobart in multiple Phase 2 and pivotal trial settings.
• The breadth of BioNTech’s oncology program, spanning more than 25 Phase 2 and Phase 3 trials, including 13 pivotal studies and several novel-novel combinations, underscores its effort to evolve into a diversified cancer-focused biopharma beyond its COVID-19 vaccine franchise.
• We’ll now examine how pumitamig’s Phase 2/3 progress in first-line lung cancer reshapes BioNTech’s investment narrative around its oncology pivot.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

BioNTech Investment Narrative Recap

To own BioNTech today, you need to believe its heavy oncology investment can offset shrinking COVID-19 revenues and persistent losses. The ASCO 2026 data for pumitamig and gotistobart support that pivot, but do not fundamentally change the near term picture where late stage trial outcomes remain the key catalyst and trial or regulatory setbacks are still the biggest risk to the business.

The most relevant recent disclosure is BioNTech’s Q1 2026 update, showing revenue of €118.1 million and a net loss of €531.9 million while reaffirming full year revenue guidance of €2.0–2.3 billion. Against that financial backdrop, the pumitamig Phase 2 ROSETTA Lung 02 results at ASCO sit at the heart of whether the company’s growing oncology spend can eventually justify current R&D intensity and help narrow losses over time.

Yet, despite the encouraging cancer data, investors should be aware that execution risk around BioNTech’s large, expensive late stage pipeline could still...

BioNTech's narrative projects €2.5 billion revenue and €374.1 million earnings by 2029. This requires a 4.0% yearly revenue decline and about a €1.5 billion earnings increase from -€1.1 billion today.

Uncover how BioNTech's forecasts yield a $131.39 fair value, a 43% upside to its current price.

Exploring Other Perspectives

Before this data, the most optimistic analysts were already assuming BioNTech could reach about €3.1 billion of revenue and €587.7 million of earnings by 2029, so these ASCO results may either reinforce or challenge those expectations depending on how you view the added clinical risk around pumitamig’s pivotal trials.

Explore 6 other fair value estimates on BioNTech - why the stock might be worth over 5x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• Our free BioNTech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BioNTech's overall financial health at a glance.

Interested In Other Possibilities?

Our top stock finds are flying under the radar-for now. Get in early:

• Find 47 companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 12 early-stage AI stocks could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.